Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung.
暂无分享,去创建一个
S. Hirohashi | T. Shibata | R. Tsuchiya | H. Asamura | Y. Kanai | Y. Matsuno | K. Tsuta | A. Kokubu | Y. Yoshida
[1] D. Sidransky,et al. Cigarette smoking is strongly associated with mutation of the K‐ras gene in patients with primary adenocarcinoma of the lung , 2001, Cancer.
[2] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[3] Y. Ishikawa,et al. High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs , 2005, Journal of Cancer Research and Clinical Oncology.
[4] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[5] A. Marchetti,et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Feng Li,et al. Mass screening for lung cancer with mobile spiral computed tomography scanner , 1998, The Lancet.
[7] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[8] S. Kido,et al. Prognostic value of bronchiolo-alveolar carcinoma component of small lung adenocarcinoma. , 1999, The Annals of thoracic surgery.
[9] K. Kerr,et al. THE PATTERN OF K‐rasMUTATION IN PULMONARY ADENOCARCINOMA DEFINES A NEW PATHWAY OF TUMOUR DEVELOPMENT IN THE HUMAN LUNG , 1997, The Journal of pathology.
[10] Andrew D. Yates,et al. Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.
[11] F. Gilliland,et al. Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. , 2003, Cancer research.
[12] Takayuki Kosaka,et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.
[13] Takashi Takahashi,et al. K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma. , 2004, The American journal of pathology.
[14] Y. Dobashi,et al. Bronchioloalveolar carcinoma of the lung 3 centimeters or less in diameter: a prognostic assessment. , 2004, The Annals of thoracic surgery.
[15] J. Gimferrer,et al. Atypical adenomatous hyperplasia of the lung problems in operative management. , 2000, Lung cancer.
[16] M. Takahama,et al. Detection of c-Ki-ras gene mutation in paraffin sections of adenocarcinoma and atypical bronchioloalveolar cell hyperplasia of human lung , 2004, Virchows Archiv.
[17] Daniel A. Haber,et al. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.
[18] S. Hirohashi,et al. Association of point mutation in c‐Ki‐ras oncogene in lung adenocarcinoma with particular reference to cytologic subtypes , 1990, Cancer.
[19] Y. Nishiwaki,et al. Monoclonality of atypical adenomatous hyperplasia of the lung. , 1999, The American journal of pathology.
[20] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Harris,et al. p53 and K-ras mutations in lung cancers from former and never-smoking women. , 2001, Cancer research.
[22] Tesshi Yamada,et al. Lung Adenocarcinoma With Mixed Bronchioloalveolar and Invasive Components: Clinicopathological Features, Subclassification by Extent of Invasive Foci, and Immunohistochemical Characterization , 2003, The American journal of surgical pathology.
[23] A. Gazdar,et al. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. , 1994, Cancer research.
[24] R. Hruban,et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. , 1996, Cancer research.
[25] A. Marchetti,et al. BRONCHIOLOALVEOLAR LUNG CARCINOMAS: K‐ras MUTATIONS ARE CONSTANT EVENTS IN THE MUCINOUS SUBTYPE , 1996, The Journal of pathology.
[26] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[27] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[28] Shih-Feng Tsai,et al. High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan , 2004, Clinical Cancer Research.
[29] Takaaki Ito,et al. Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. , 1999, American journal of clinical pathology.
[30] H. Tsukuma,et al. A comparison of trends in the incidence rate of lung cancer by histological type in the Osaka Cancer Registry, Japan and in the Surveillance, Epidemiology and End Results Program, USA. , 2003, Japanese journal of clinical oncology.
[31] J. Minna,et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.
[32] William Pao,et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] H. Ohmatsu,et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. , 1996, Radiology.